comprehensive -WSS

comprehensive

author：knowledge 2025-09-28 01:37:36 - browse：15

Janet Woodcock -- health policy coverage from STAT — Janet Woodcock, the FDA's principal deputy commissioner Chip Somodevilla/Getty Images

WASHINGTON — It’s the end of an era for the Food and Drug Administration’s longtime drug chief, but she’s drawn the battle plans for the agency’s next chapter.

Janet Woodcock joined the FDA’s biologics division in 1986 but soon moved to the drug side, where over nearly three decades, she oversaw hundreds of reviews, new and evolving classes of therapies and several clashes with Congress and patient advocates. In recent years, she also warded off attacks on the agency’s decisionmaking during the Covid-19 pandemic, particularly when the agency veteran took the acting commissioner role during President Biden’s long search for a permanent leader, and took charge of a vast reorganization plan sparked by the baby formula crisis.

Some of those efforts still hang in the balance as she departs this week. Critics argue that under her oversight, the drug division worked too closely with pharmaceutical companies to give broad approvals to new medicines like Biogen’s Aduhelm or so-called accelerated approval to controversial therapies like Sarepta’s Duchenne muscular dystrophy medicine Exondys 51, which is still in the midst of post-marketing studies to prove its effectiveness.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Diagnostic tests are hitting their mathematical limits

WSS

Why Charlie Gard's case is so disturbing to Americans

What to do when lifesaving products contribute to climate change

Why Charlie Gard's case is so disturbing to Americans

Why Charlie Gard's case is so disturbing to Americans

UnitedHealth’s Optum accused of antitrust violations in California

Pediatric cancer treatments threatened by a new FDA policy

hotspot

comprehensive

explore

What does generative AI mean for health care? We asked experts

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

How to save PrEP access — and even expand it

U.K. Biobank has 500,000 peoples' genome sequences available

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

FDA panel signals lack of confidence in Amgen cancer drug data

Peter Hotez and the public health issue of online harassment

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

explore

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

What to do when lifesaving products contribute to climate change

Organ aging and disease risk measured by new blood test

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

When women are denied an abortion, their children fare worse than peers

Chan Zuckerberg Biohub Chicago to focus on inflammation

hotspot

focus

Wikipedia

hotspot